Discontinued — last reported Q4 '24
Moderna Grant revenue — Deferred Revenue decreased by 18.2% to $9.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 125.0%, from $4.00M to $9.00M. Over 3 years (FY 2021 to FY 2024), Grant revenue — Deferred Revenue shows an upward trend with a 3.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates a growing pipeline of funded research that will be recognized as revenue in future periods.
This represents the portion of grant funding received in advance that has not yet been recognized as revenue because the...
Standard across industries with long-term contracts; comparable to deferred revenue in software or construction sectors.
mrna_segment_grant_revenue_deferred_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.00M | $6.00M | $6.00M | $6.00M | $5.00M | $5.00M | $4.00M | $3.00M | $2.00M | $4.00M | $4.00M | $4.00M | $4.00M | $11.00M | $9.00M |
| QoQ Change | — | -25.0% | +0.0% | +0.0% | -16.7% | +0.0% | -20.0% | -25.0% | -33.3% | +100.0% | +0.0% | +0.0% | +0.0% | +175.0% | -18.2% |
| YoY Change | — | — | — | — | -37.5% | -16.7% | -33.3% | -50.0% | -60.0% | -20.0% | +0.0% | +33.3% | +100.0% | +175.0% | +125.0% |